Abstract
Some 17,000 people descended on Boston during the first week of June for the annual meeting of the Biotechnology Innovation Organization (BIO). If the crowds were any indication, business is booming. “This has been by far the most successful BIO convention we’ve ever had,” said John Maraganore, CEO of Alnylam Pharmaceuticals and chair of BIO. Attendees set a Guinness world record for the largest business-partnering event, with more than 45,000 meetings among people from across the globe. “If you want to be in the business of biotechnology, you need to be here,” said Manu Nair, who came to Boston from the Oklahoma Medical Research Foundation. Biotech investment is on track for a record year. “The first quarter was very strong for venture capital investing, and those trends seem durable,” said Glen Giovannetti, global biotechnology leader at the consulting firm EY. Cancer companies, especially immuno-oncology start-ups, are attracting a disproportionate amount
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
